To achieve the goals set out in its ‘Vision 2030’, argenx has set the following priorities for 2025: Expand the global VYVGART opportunity by reaching more patients broadly across MG, CIDP and ITP ...
NX-210c is under clinical development by Axoltis Pharma and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 81% ...